Does the media favor VANI or COCH?

In the previous week, Vivani Medical and Vivani Medical both had 2 articles in the media. Vivani Medical's average media sentiment score of 0.94 equaled Envoy Medical'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vivani Medical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Envoy Medical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to COCH or SMTI?

In the previous week, Sanara MedTech had 1 more articles in the media than Envoy Medical. MarketBeat recorded 3 mentions for Sanara MedTech and 2 mentions for Envoy Medical. Envoy Medical's average media sentiment score of 0.94 beat Sanara MedTech's score of 0.63 indicating that Envoy Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Envoy Medical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sanara MedTech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, PDEX or COCH?

Pro-Dex has higher revenue and earnings than Envoy Medical. Envoy Medical is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pro-Dex $66.59M 3.20 $8.98M $3.62 18.44 Envoy Medical $240K 225.84 -$23.76M -$1.01 N/A

Is PDEX or COCH more profitable?

Pro-Dex has a net margin of 16.08% compared to Envoy Medical's net margin of -9,875.64%. Pro-Dex's return on equity of 22.78% beat Envoy Medical's return on equity. Company Net Margins Return on Equity Return on Assets Pro-Dex 16.08% 22.78% 14.30% Envoy Medical -9,875.64% N/A -177.92%

Does the media favor PDEX or COCH?

In the previous week, Pro-Dex and Pro-Dex both had 2 articles in the media. Envoy Medical's average media sentiment score of 0.94 beat Pro-Dex's score of 0.18 indicating that Envoy Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pro-Dex 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Envoy Medical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is TLSI or COCH more profitable?

TriSalus Life Sciences has a net margin of -60.85% compared to Envoy Medical's net margin of -9,875.64%. Company Net Margins Return on Equity Return on Assets TriSalus Life Sciences -60.85% N/A -69.91% Envoy Medical -9,875.64% N/A -177.92%

Does the media favor TLSI or COCH?

In the previous week, TriSalus Life Sciences had 1 more articles in the media than Envoy Medical. MarketBeat recorded 3 mentions for TriSalus Life Sciences and 2 mentions for Envoy Medical. TriSalus Life Sciences' average media sentiment score of 1.89 beat Envoy Medical's score of 0.94 indicating that TriSalus Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TriSalus Life Sciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Envoy Medical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, EMBC or COCH?

Embecta has higher revenue and earnings than Envoy Medical. Envoy Medical is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Embecta $1.04B 0.20 $95.40M $1.90 1.84 Envoy Medical $240K 225.84 -$23.76M -$1.01 N/A

Is EMBC or COCH more profitable?

Embecta has a net margin of 10.73% compared to Envoy Medical's net margin of -9,875.64%. Envoy Medical's return on equity of 0.00% beat Embecta's return on equity. Company Net Margins Return on Equity Return on Assets Embecta 10.73% -23.96% 14.12% Envoy Medical -9,875.64% N/A -177.92%

Does the media favor EMBC or COCH?

In the previous week, Embecta had 4 more articles in the media than Envoy Medical. MarketBeat recorded 6 mentions for Embecta and 2 mentions for Envoy Medical. Envoy Medical's average media sentiment score of 0.94 beat Embecta's score of 0.20 indicating that Envoy Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Embecta 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Envoy Medical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Envoy Medical (COCH) Competitors

$0.70 +0.01 (+0.71%)

Closing price 06/2/2026 04:00 PM Eastern

Extended Trading

$0.68 -0.02 (-2.84%)

As of 07:00 AM Eastern

Compare

COCH vs. VANI, SMTI, PDEX, TLSI, and EMBC

Should you buy Envoy Medical stock or one of its competitors? MarketBeat compares Envoy Medical with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Envoy Medical include Vivani Medical (VANI), Sanara MedTech (SMTI), Pro-Dex (PDEX), TriSalus Life Sciences (TLSI), and Embecta (EMBC). These companies are all part of the "medical equipment" industry.

How does Envoy Medical compare to Vivani Medical?

Vivani Medical (NASDAQ:VANI) and Envoy Medical (NASDAQ:COCH) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, media sentiment and dividends.

Vivani Medical has a beta of 2.31, indicating that its share price is 131% more volatile than the broader market. Comparatively, Envoy Medical has a beta of 1.9, indicating that its share price is 90% more volatile than the broader market.

Envoy Medical has higher revenue and earnings than Vivani Medical. Vivani Medical is trading at a lower price-to-earnings ratio than Envoy Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivani Medical	N/A	N/A	-$26.61M	-$0.40	N/A
Envoy Medical	$240K	225.84	-$23.76M	-$1.01	N/A

Vivani Medical presently has a consensus price target of $3.50, suggesting a potential upside of 169.23%. Envoy Medical has a consensus price target of $2.50, suggesting a potential upside of 254.61%. Given Envoy Medical's higher possible upside, analysts clearly believe Envoy Medical is more favorable than Vivani Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivani Medical	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Envoy Medical	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Vivani Medical has a net margin of 0.00% compared to Envoy Medical's net margin of -9,875.64%. Envoy Medical's return on equity of 0.00% beat Vivani Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vivani Medical	N/A	-264.04%	-79.85%
Envoy Medical	-9,875.64%	N/A	-177.92%

In the previous week, Vivani Medical and Vivani Medical both had 2 articles in the media. Vivani Medical's average media sentiment score of 0.94 equaled Envoy Medical'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vivani Medical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Envoy Medical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

6.8% of Vivani Medical shares are held by institutional investors. Comparatively, 8.6% of Envoy Medical shares are held by institutional investors. 53.3% of Vivani Medical shares are held by company insiders. Comparatively, 7.1% of Envoy Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Envoy Medical beats Vivani Medical on 6 of the 11 factors compared between the two stocks.

How does Envoy Medical compare to Sanara MedTech?

Envoy Medical (NASDAQ:COCH) and Sanara MedTech (NASDAQ:SMTI) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, media sentiment and analyst recommendations.

Envoy Medical has a beta of 1.9, indicating that its share price is 90% more volatile than the broader market. Comparatively, Sanara MedTech has a beta of 1.21, indicating that its share price is 21% more volatile than the broader market.

Sanara MedTech has a net margin of -31.23% compared to Envoy Medical's net margin of -9,875.64%. Envoy Medical's return on equity of 0.00% beat Sanara MedTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Envoy Medical	-9,875.64%	N/A	-177.92%
Sanara MedTech	-31.23%	-3.19%	-0.56%

In the previous week, Sanara MedTech had 1 more articles in the media than Envoy Medical. MarketBeat recorded 3 mentions for Sanara MedTech and 2 mentions for Envoy Medical. Envoy Medical's average media sentiment score of 0.94 beat Sanara MedTech's score of 0.63 indicating that Envoy Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Envoy Medical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sanara MedTech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

8.6% of Envoy Medical shares are owned by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are owned by institutional investors. 7.1% of Envoy Medical shares are owned by insiders. Comparatively, 42.0% of Sanara MedTech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Envoy Medical has higher earnings, but lower revenue than Sanara MedTech. Sanara MedTech is trading at a lower price-to-earnings ratio than Envoy Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Envoy Medical	$240K	225.84	-$23.76M	-$1.01	N/A
Sanara MedTech	$103.12M	1.89	-$37.56M	-$3.77	N/A

Envoy Medical presently has a consensus target price of $2.50, indicating a potential upside of 254.61%. Sanara MedTech has a consensus target price of $34.00, indicating a potential upside of 59.92%. Given Envoy Medical's higher possible upside, analysts plainly believe Envoy Medical is more favorable than Sanara MedTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Envoy Medical	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Sanara MedTech	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Envoy Medical beats Sanara MedTech on 9 of the 15 factors compared between the two stocks.

How does Envoy Medical compare to Pro-Dex?

Pro-Dex (NASDAQ:PDEX) and Envoy Medical (NASDAQ:COCH) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends.

15.3% of Pro-Dex shares are owned by institutional investors. Comparatively, 8.6% of Envoy Medical shares are owned by institutional investors. 45.9% of Pro-Dex shares are owned by company insiders. Comparatively, 7.1% of Envoy Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Pro-Dex and Pro-Dex both had 2 articles in the media. Envoy Medical's average media sentiment score of 0.94 beat Pro-Dex's score of 0.18 indicating that Envoy Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pro-Dex	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Envoy Medical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pro-Dex currently has a consensus price target of $70.00, indicating a potential upside of 4.87%. Envoy Medical has a consensus price target of $2.50, indicating a potential upside of 254.61%. Given Envoy Medical's higher probable upside, analysts plainly believe Envoy Medical is more favorable than Pro-Dex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pro-Dex	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33
Envoy Medical	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Pro-Dex has a net margin of 16.08% compared to Envoy Medical's net margin of -9,875.64%. Pro-Dex's return on equity of 22.78% beat Envoy Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pro-Dex	16.08%	22.78%	14.30%
Envoy Medical	-9,875.64%	N/A	-177.92%

Pro-Dex has a beta of -0.02, meaning that its stock price is 102% less volatile than the broader market. Comparatively, Envoy Medical has a beta of 1.9, meaning that its stock price is 90% more volatile than the broader market.

Pro-Dex has higher revenue and earnings than Envoy Medical. Envoy Medical is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pro-Dex	$66.59M	3.20	$8.98M	$3.62	18.44
Envoy Medical	$240K	225.84	-$23.76M	-$1.01	N/A

Summary

Pro-Dex beats Envoy Medical on 10 of the 14 factors compared between the two stocks.

How does Envoy Medical compare to TriSalus Life Sciences?

TriSalus Life Sciences (NASDAQ:TLSI) and Envoy Medical (NASDAQ:COCH) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

TriSalus Life Sciences presently has a consensus target price of $7.50, suggesting a potential upside of 124.55%. Envoy Medical has a consensus target price of $2.50, suggesting a potential upside of 254.61%. Given Envoy Medical's higher probable upside, analysts clearly believe Envoy Medical is more favorable than TriSalus Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TriSalus Life Sciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Envoy Medical	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

TriSalus Life Sciences has a beta of 0.48, meaning that its stock price is 52% less volatile than the broader market. Comparatively, Envoy Medical has a beta of 1.9, meaning that its stock price is 90% more volatile than the broader market.

Envoy Medical has lower revenue, but higher earnings than TriSalus Life Sciences. TriSalus Life Sciences is trading at a lower price-to-earnings ratio than Envoy Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TriSalus Life Sciences	$44.88M	4.57	-$39.23M	-$1.41	N/A
Envoy Medical	$240K	225.84	-$23.76M	-$1.01	N/A

2.6% of TriSalus Life Sciences shares are owned by institutional investors. Comparatively, 8.6% of Envoy Medical shares are owned by institutional investors. 16.3% of TriSalus Life Sciences shares are owned by insiders. Comparatively, 7.1% of Envoy Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, TriSalus Life Sciences had 1 more articles in the media than Envoy Medical. MarketBeat recorded 3 mentions for TriSalus Life Sciences and 2 mentions for Envoy Medical. TriSalus Life Sciences' average media sentiment score of 1.89 beat Envoy Medical's score of 0.94 indicating that TriSalus Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TriSalus Life Sciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Envoy Medical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TriSalus Life Sciences has a net margin of -60.85% compared to Envoy Medical's net margin of -9,875.64%.

Company	Net Margins	Return on Equity	Return on Assets
TriSalus Life Sciences	-60.85%	N/A	-69.91%
Envoy Medical	-9,875.64%	N/A	-177.92%

Summary

TriSalus Life Sciences beats Envoy Medical on 8 of the 15 factors compared between the two stocks.

How does Envoy Medical compare to Embecta?

Embecta (NASDAQ:EMBC) and Envoy Medical (NASDAQ:COCH) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation.

Embecta has higher revenue and earnings than Envoy Medical. Envoy Medical is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Embecta	$1.04B	0.20	$95.40M	$1.90	1.84
Envoy Medical	$240K	225.84	-$23.76M	-$1.01	N/A

In the previous week, Embecta had 4 more articles in the media than Envoy Medical. MarketBeat recorded 6 mentions for Embecta and 2 mentions for Envoy Medical. Envoy Medical's average media sentiment score of 0.94 beat Embecta's score of 0.20 indicating that Envoy Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Embecta	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Envoy Medical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Embecta has a net margin of 10.73% compared to Envoy Medical's net margin of -9,875.64%. Envoy Medical's return on equity of 0.00% beat Embecta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Embecta	10.73%	-23.96%	14.12%
Envoy Medical	-9,875.64%	N/A	-177.92%

93.8% of Embecta shares are held by institutional investors. Comparatively, 8.6% of Envoy Medical shares are held by institutional investors. 1.3% of Embecta shares are held by insiders. Comparatively, 7.1% of Envoy Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Embecta currently has a consensus price target of $11.00, indicating a potential upside of 215.19%. Envoy Medical has a consensus price target of $2.50, indicating a potential upside of 254.61%. Given Envoy Medical's stronger consensus rating and higher possible upside, analysts clearly believe Envoy Medical is more favorable than Embecta.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Embecta	3 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.40
Envoy Medical	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Embecta has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market. Comparatively, Envoy Medical has a beta of 1.9, indicating that its stock price is 90% more volatile than the broader market.

Summary

Embecta and Envoy Medical tied by winning 8 of the 16 factors compared between the two stocks.

Get Envoy Medical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding COCH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

COCH vs. The Competition

Export

Metric	Envoy Medical	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$53.82M	$7.24B	$6.32B	$12.58B
Dividend Yield	N/A	1.21%	2.69%	5.45%
P/E Ratio	-0.70	44.66	21.04	24.56
Price / Sales	225.84	86.81	559.52	127.44
Price / Cash	N/A	24.40	42.31	57.88
Price / Book	-1.68	7.27	9.93	6.75
Net Income	-$23.76M	$159.22M	$3.56B	$337.19M
7 Day Performance	1.82%	2.24%	-0.44%	1.88%
1 Month Performance	3.52%	6.42%	4.59%	6.59%
1 Year Performance	-54.52%	3.44%	27.59%	35.52%

Envoy Medical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
COCH Envoy Medical	2.355 of 5 stars	$0.71 +0.7%	$2.50 +254.6%	-53.0%	$53.82M	$240K	N/A	34	News Coverage High Trading Volume
VANI Vivani Medical	2.9924 of 5 stars	$1.27 +2.0%	$3.50 +176.7%	+5.7%	$109.09M	N/A	N/A	20	Gap Up
SMTI Sanara MedTech	1.7738 of 5 stars	$23.10 +0.7%	$34.00 +47.2%	-26.9%	$211.64M	$107.48M	N/A	60
PDEX Pro-Dex	2.0856 of 5 stars	$63.33 -2.8%	$70.00 +10.5%	+70.1%	$202.01M	$66.59M	17.49	140	News Coverage Positive News
TLSI TriSalus Life Sciences	4.0413 of 5 stars	$3.14 -2.5%	$7.50 +138.9%	-35.9%	$192.86M	$45.15M	N/A	106	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:COCH) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Envoy Medical (COCH) Competitors

COCH vs. VANI, SMTI, PDEX, TLSI, and EMBC

How does Envoy Medical compare to Vivani Medical?

Summary

How does Envoy Medical compare to Sanara MedTech?

Summary

How does Envoy Medical compare to Pro-Dex?

Summary

How does Envoy Medical compare to TriSalus Life Sciences?

Summary

How does Envoy Medical compare to Embecta?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COCH vs. The Competition

Envoy Medical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Envoy Medical (COCH) Competitors

COCH vs. VANI, SMTI, PDEX, TLSI, and EMBC

How does Envoy Medical compare to Vivani Medical?

Which has more risk & volatility, VANI or COCH?

Which has preferable valuation and earnings, VANI or COCH?

Do analysts recommend VANI or COCH?

Is VANI or COCH more profitable?

Does the media favor VANI or COCH?

Do institutionals & insiders hold more shares of VANI or COCH?

Summary

How does Envoy Medical compare to Sanara MedTech?

Which has more risk and volatility, COCH or SMTI?

Is COCH or SMTI more profitable?

Does the media refer more to COCH or SMTI?

Do insiders and institutionals believe in COCH or SMTI?

Which has stronger earnings and valuation, COCH or SMTI?

Do analysts prefer COCH or SMTI?

Summary

How does Envoy Medical compare to Pro-Dex?

Do institutionals & insiders have more ownership in PDEX or COCH?

Does the media favor PDEX or COCH?

Do analysts rate PDEX or COCH?

Is PDEX or COCH more profitable?

Which has more risk and volatility, PDEX or COCH?

Which has better earnings and valuation, PDEX or COCH?

Summary

How does Envoy Medical compare to TriSalus Life Sciences?

Do analysts recommend TLSI or COCH?

Which has more risk & volatility, TLSI or COCH?

Which has higher valuation and earnings, TLSI or COCH?

Do institutionals and insiders hold more shares of TLSI or COCH?

Does the media favor TLSI or COCH?

Is TLSI or COCH more profitable?

Summary

How does Envoy Medical compare to Embecta?

Which has stronger earnings and valuation, EMBC or COCH?

Does the media favor EMBC or COCH?

Is EMBC or COCH more profitable?

Do institutionals and insiders believe in EMBC or COCH?

Do analysts rate EMBC or COCH?

Which has more volatility & risk, EMBC or COCH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COCH vs. The Competition

Envoy Medical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools